Virtual Library
Start Your Search
Hasna Bouchaab
Author of
-
+
MA05 - Update on Clinical Trials and Treatments (ID 123)
- Event: WCLC 2019
- Type: Mini Oral Session
- Track: Mesothelioma
- Presentations: 1
- Now Available
- Moderators:Seiki Hasegawa, Enrico Ruffini, Angel Artal
- Coordinates: 9/08/2019, 13:30 - 15:00, Melbourne (1991)
-
+
MA05.01 - Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma (Now Available) (ID 1955)
13:30 - 15:00 | Author(s): Hasna Bouchaab
- Abstract
- Presentation
Background
Surgical resection plays an important role in the management of selected patients with malignant pleural mesothelioma (MPM). Early experience with anti-PD-1 immunotherapy showed promise in MPM, but it is yet uncertain if it can improve outcomes when tumour relapses following surgical resection, radiotherapy and chemotherapy. We reviewed our experience in patients who received Pembrolizumab or Nivolumab following multimodality therapy.
Method
Retrospective study including patients with histologically-proven MPM having completed multimodality therapy and received anti-PD-1 immunotherapy as 2nd or 3rd line treatment. Data were retrieved from a prospective mesothelioma database. Histopathology, BAP1, MTAP and PD-L1 (22C3) immunohistochemistry were performed on surgical specimens and reported by a senior pathologist. All patients had chest computed tomography and positron emission tomography (PET-CT) as part of their normal follow-up. Response evaluation was determined using RECIST 1.1 criteria.
Result
16 patients received anti-PD-1 immunotherapy between August 2015 and March 2019. All patients had total pleurectomy/decortication, prophylactic radiotherapy (21Gy/3) and systemic chemotherapy based on pemetrexed and platinum. Median age was 68.5 years, with male predominance (13/16). 56% had epithelioid type, 44% had biphasic type. Median time to starting immunotherapy was 20 months (range 11-42) following surgery. Median ECOG performance status was 0. Twelve patients received Pembrolizumab and 4 received Nivolumab. Median number of cycles of anti-PD-1 therapy received was 5 (range 1-33). Disease control rate at 12 weeks was 56.2% and 7 (43.7%) patients had disease progression. Adverse events were observed in 6 patients (one Grade 3). Eight patients were alive by 1st April 2019. Median OS from starting immunotherapy was 13.5 months. Three patients received treatment for 14 months or more. Five patients started further therapy after discontinuing immunotherapy.
Conclusion
In our cohort, second or third-line anti-PD-1 immunotherapy showed efficacy with DCR comparable to non-surgical setting. Further studies are warranted to validate our preliminary findings.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P2.12 - Small Cell Lung Cancer/NET (ID 180)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.12-21 - Outcomes with Immune Checkpoint Inhibitors (ICI) for Relapsed Small Cell Lung Cancer (SCLC) in a Swiss Cohort (ID 1026)
10:15 - 18:15 | Author(s): Hasna Bouchaab
- Abstract
Background
Chemotherapy for relapsed small-cell lung cancer (SCLC) has limited activity. Results from early clinical trials showed promising outcomes in a subset of patients with relapsed SCLC receiving ICI. Therefore, nivolumab +/- ipilimumab, pembrolizumab or atezolizumab have been used off-label in Switzerland.
Method
9 cancer centers in Switzerland contributed data to this retrospective cohort of patients who received off-label ICI for relapsed SCLC. Patient characteristics including age, smoking status, stage at diagnosis and previous treatments were collected. Outcomes of ICI were assessed by the local investigators using standard RECIST v1.1 criteria. Tumor tissues were assessed centrally for PD-L1 expression, tumor mutational burden and immune-related gene expression signatures.
Result
45 patients were included between November 2016 and January 2019. Median age was 63 years. 73% were males, 4% never smokers and 18% had a performance status (PS) ≥2. ICIs were given as second line treatment in 24 patients (53%). 24 patients (53%) received combination immunotherapy with ipiliumumab and nivolumab. 28 patients (62%) had undergone tumor irradiation (RT) prior to or during ICI. In the entire population, the overall response rate was 31%, while 49% had progressive disease as best response. Median progression-free survival was 2.5 months and median overall survival 6.5 months. There was no significant association between type of ICI (mono vs. combo) or prior RT vs. no RT with survival outcomes in a multivariate analysis. There were no new safety signals. One patient died of immune-related pneumonitis.
Conclusion
This is the first report of “real-world” data on ICI in relapsed SCLC also including patients with poor PS. We confirm the efficacy and safety of ICI in relapsed SCLC as previously shown in clinical trials. No clinical prognostic marker could be identified. Results on the prognostic value of tissue-based biomarkers will be presented at the meeting.
